MX2017007243A - Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6. - Google Patents

Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6.

Info

Publication number
MX2017007243A
MX2017007243A MX2017007243A MX2017007243A MX2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A MX 2017007243 A MX2017007243 A MX 2017007243A
Authority
MX
Mexico
Prior art keywords
applications
micro
troncal
epitelial
lgr6
Prior art date
Application number
MX2017007243A
Other languages
English (en)
Spanish (es)
Inventor
M Lough Denver
Original Assignee
Polarityte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56078499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017007243(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polarityte Inc filed Critical Polarityte Inc
Publication of MX2017007243A publication Critical patent/MX2017007243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/362—Skin, e.g. dermal papillae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017007243A 2014-12-02 2015-12-01 Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6. MX2017007243A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086526P 2014-12-02 2014-12-02
US14/954,335 US10926001B2 (en) 2014-12-02 2015-11-30 Methods related to minimally polarized functional units
PCT/US2015/063114 WO2016089825A1 (en) 2014-12-02 2015-12-01 Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells

Publications (1)

Publication Number Publication Date
MX2017007243A true MX2017007243A (es) 2018-01-25

Family

ID=56078499

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007243A MX2017007243A (es) 2014-12-02 2015-12-01 Metodos para desarrollo y uso de unidades micro-agregadas de celulas funcionales polarizadas minimamente en aplicaciones en tejidos utilizando celulas troncales epiteliales que expresan lgr4, lgr5 y lgr6.
MX2023001655A MX2023001655A (es) 2014-12-02 2017-06-05 Composiciones que comprenden celulas troncales que expresan lgr y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001655A MX2023001655A (es) 2014-12-02 2017-06-05 Composiciones que comprenden celulas troncales que expresan lgr y usos de las mismas.

Country Status (21)

Country Link
US (7) US10926001B2 (cg-RX-API-DMAC10.html)
EP (2) EP3227431B1 (cg-RX-API-DMAC10.html)
JP (3) JP6791854B2 (cg-RX-API-DMAC10.html)
KR (5) KR20210043024A (cg-RX-API-DMAC10.html)
CN (1) CN107250348B (cg-RX-API-DMAC10.html)
AU (3) AU2015355187C1 (cg-RX-API-DMAC10.html)
BR (1) BR112017011808A2 (cg-RX-API-DMAC10.html)
CA (1) CA2969707C (cg-RX-API-DMAC10.html)
CO (1) CO2017006640A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170296A (cg-RX-API-DMAC10.html)
EA (1) EA201791125A1 (cg-RX-API-DMAC10.html)
GB (2) GB2569056B (cg-RX-API-DMAC10.html)
HK (1) HK1250515A1 (cg-RX-API-DMAC10.html)
IL (2) IL252613B (cg-RX-API-DMAC10.html)
MX (2) MX2017007243A (cg-RX-API-DMAC10.html)
MY (1) MY184931A (cg-RX-API-DMAC10.html)
NZ (2) NZ733433A (cg-RX-API-DMAC10.html)
PH (1) PH12017501009B1 (cg-RX-API-DMAC10.html)
SG (2) SG10201914058QA (cg-RX-API-DMAC10.html)
WO (1) WO2016089825A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201703907B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913690A (zh) * 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
CA3088129A1 (en) * 2018-01-26 2019-08-01 Polarityte, Inc. Composite-interfacing biomaterial accelerant substrate
WO2019148143A1 (en) * 2018-01-26 2019-08-01 Polarityte, Inc. Complex living interface-coordinated self-assembling materials (clicsam)
FR3082123B1 (fr) 2018-06-07 2020-10-16 Urgo Rech Innovation Et Developpement Pansement cellularise et son procede de fabrication
JP2024006681A (ja) * 2022-07-04 2024-01-17 学校法人近畿大学 生体材料
WO2025166131A1 (en) * 2024-02-01 2025-08-07 Board Of Regents, The University Of Texas System Compositions and methods for treating bone and muscle injuries

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126881A1 (en) * 2002-09-06 2004-07-01 Vincent Ronfard Fibrin cell supports and methods of use thereof
WO2006008009A2 (en) 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)
US20060154365A1 (en) 2004-08-30 2006-07-13 Anthony Ratcliffe Cultured three dimensional tissues and uses thereof
US8053559B2 (en) 2005-10-27 2011-11-08 Coloplast A/S Biodegradable scaffold with ECM material
US20100328320A1 (en) 2006-07-13 2010-12-30 Kerstna Juergen Medical information management in a patient information hub system
US8366723B2 (en) 2006-08-03 2013-02-05 Rassman Licensing, Llc Hair harvesting device and method with localized subsurface dermal fluid insertion
WO2008031767A1 (en) 2006-09-12 2008-03-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Cell culture of keratinocytes under non-differentiating conditions
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
FI20095355A0 (fi) 2009-04-01 2009-04-01 Helsingin Yliopisto Regeneroituva aktiivinen matriisi ja sen käytöt
JP2012531185A (ja) 2009-06-25 2012-12-10 株式会社 資生堂 Aff‐4を指標とした抗白髪剤のスクリーニング方法
US20110130711A1 (en) 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US20130101564A1 (en) 2010-06-30 2013-04-25 Jinxi Chen Method for preparing dermis tissue cells aggregation and uses thereof
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
JP6215216B2 (ja) 2011-10-27 2017-10-18 ウニヴェルジテート ライプチッヒ 毛包外毛根鞘からメラノサイトを誘導する方法および移植のための調製
JP6186997B2 (ja) 2012-08-07 2017-08-30 日油株式会社 塗布型帯電防止剤
US9655930B2 (en) 2012-10-01 2017-05-23 Aderans Research Institute, Inc. Compositions and methods for producing reconstituted skin
US20140106447A1 (en) 2012-10-12 2014-04-17 Mimedx Group, Inc. Compositions and methods for recruiting stem cells
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
US9592257B2 (en) 2013-10-11 2017-03-14 MWV Cell, LLC Complete human skin organ generated from culture-expanded cells
CN103550828B (zh) * 2013-10-17 2016-01-27 中国科学院动物研究所 一种基于毛囊干细胞和硅凝胶敷料的皮肤重建方法
TWI548413B (zh) 2014-11-07 2016-09-11 國立臺灣大學 誘導毛囊新生的皮膚萃取物、組合物及其用途

Also Published As

Publication number Publication date
CR20170296A (es) 2018-01-25
EP3227431B1 (en) 2025-01-29
US11266765B2 (en) 2022-03-08
WO2016089825A1 (en) 2016-06-09
EP3227431A4 (en) 2019-01-02
AU2019240603B2 (en) 2023-02-09
GB201902819D0 (en) 2019-04-17
GB2549872A (en) 2017-11-01
GB201710646D0 (en) 2017-08-16
US20160151540A1 (en) 2016-06-02
PH12017501009A1 (en) 2017-12-11
US20190046691A1 (en) 2019-02-14
US20220241464A1 (en) 2022-08-04
AU2023202857A1 (en) 2023-05-25
BR112017011808A2 (en) 2018-02-27
KR20190111167A (ko) 2019-10-01
US11338060B2 (en) 2022-05-24
US20180154044A1 (en) 2018-06-07
NZ755260A (en) 2021-12-24
IL287488B2 (en) 2023-06-01
AU2015355187B2 (en) 2019-10-03
EP3227431A1 (en) 2017-10-11
CA2969707A1 (en) 2016-06-09
AU2015355187C1 (en) 2020-02-20
EP4438128A2 (en) 2024-10-02
US12465669B2 (en) 2025-11-11
EP4438128A3 (en) 2024-11-13
CN107250348A (zh) 2017-10-13
JP2020182880A (ja) 2020-11-12
AU2015355187A1 (en) 2017-06-29
HK1245327A1 (zh) 2018-08-24
SG10201914058QA (en) 2020-03-30
US10926001B2 (en) 2021-02-23
AU2019240603A1 (en) 2019-10-17
MY184931A (en) 2021-04-30
MX2023001655A (es) 2023-04-24
JP2017538411A (ja) 2017-12-28
HK1250515A1 (zh) 2018-12-21
GB2569056A (en) 2019-06-05
US11000629B2 (en) 2021-05-11
US20230181797A1 (en) 2023-06-15
CA2969707C (en) 2019-08-20
EP3227431C0 (en) 2025-01-29
CO2017006640A2 (es) 2017-11-21
EA201791125A1 (ru) 2018-06-29
US20210322643A1 (en) 2021-10-21
CN107250348B (zh) 2021-09-03
KR20210043024A (ko) 2021-04-20
US20180154043A1 (en) 2018-06-07
JP6791854B2 (ja) 2020-11-25
ZA201703907B (en) 2023-03-29
GB2569056B (en) 2020-01-01
IL287488A (en) 2021-12-01
NZ733433A (en) 2019-08-30
JP2019088299A (ja) 2019-06-13
US11596714B2 (en) 2023-03-07
PH12017501009B1 (en) 2022-01-21
KR20180136587A (ko) 2018-12-24
IL252613B (en) 2021-12-01
KR20170098844A (ko) 2017-08-30
SG11201704502RA (en) 2017-06-29
KR20180136588A (ko) 2018-12-24
IL252613A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
CO2017006640A2 (es) Metodos para el desarrollo y uso de unidades de micro-agregado de funcion celular polarizada en aplicaciones de tejido usando lgr4, lgr5 y lgr 6 que expresan celulas madre epiteliales
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
MX2015000990A (es) Analogos del glucagon.
MX2020005634A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
MX387259B (es) Agonistas receptores de glp-1 y usos de los mismos
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2015014408A (es) Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
MX2021012539A (es) Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita.
MX384175B (es) Métodos para seleccionar una línea de células t y el donador de la misma para terapia celular adoptiva.
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
PE20181346A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
UY36150A (es) Derivados de naftiridinadiona
MX386476B (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201691596A1 (ru) Составы гепарина для наружного применения
CL2009001221A1 (es) Uso de un androgeno y/o un modulador selectivo del receptor de androgeno para preparar un medicamento para el tratamiento de la insuficiencia cardiaca o para retardar o detener el avance de la insuficiencia cardiaca en un sujeto humano de sexo femenino.
AR101582A1 (es) Tratamiento de tejido mamario con óxido nítrico
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares